SCHEMBL1292971

SCHEMBL1292971

[CH2]C(OCCC(C)CCC=C(C)C)OCCC(C)CCC=C(C)C

nearest known ligand 0.59

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.59
ALDH1A1 P00352 2/20 0.55
NFE2L2 Q16236 1/20 0.43
USP2 O75604 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 1/20 0.38
GGPS1 O95749 2/20 0.35
FDPS P14324 2/20 0.35
EPHX2 P34913 1/20 0.34
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27200268 0.86 ALOX15 (0.65) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL3152826 0.85 ALOX15 (0.62) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL17955365 0.85 ALOX15 (0.62) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL16902070 0.85 ALOX15 (0.62) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL17955363 0.85 ALOX15 (0.62) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL4448320 0.81 ALOX15 (0.62) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL8397532 0.80 ALOX15 (0.67) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL8059226 0.80 ALOX15 (0.67) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL5604473 0.80 ALOX15 (0.57) ALOX15ALDH1A1NFE2L2USP2TDP1
SCHEMBL5604557 0.80 ALOX15 (0.57) ALOX15ALDH1A1NFE2L2USP2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180360706-A1 Delivery Particles PROCTER & GAMBLE (US) 2018-12-20 US claimed
US-20110268802-A1 DELIVERY PARTICLE THE PROCTER & GAMBLE COMPANY 2011-11-03 US claimed
US-20240238748-A1 CAPSULES PROCTER & GAMBLE (US) 2024-07-18 US disclosed
US-11904287-B2 Capsules THE PROCTER & GAMBLE COMPANY (US) 2024-02-20 US disclosed
US-20230201786-A1 Methods of Making Capsules PROCTER & GAMBLE (US) 2023-06-29 US disclosed
US-11628413-B2 Methods of making capsules THE PROCTER & GAMBLE COMPANY (US) 2023-04-18 US disclosed
US-20220409497-A1 DELIVERY PARTICLE PROCTER & GAMBLE (US) 2022-12-29 US disclosed
US-20220258118-A1 Capsules PROCTER & GAMBLE (US) 2022-08-18 US disclosed
EP-3956427-A1 CAPSULES The Procter & Gamble Company (US) 2022-02-23 EP disclosed
EP-3955890-A1 CAPSULES The Procter & Gamble Company (US) 2022-02-23 EP disclosed
EP-3956054-A1 METHODS OF MAKING CAPSULES The Procter & Gamble Company (US) 2022-02-23 EP disclosed
EP-2563507-A2 DELIVERY PARTICLES The Procter & Gamble Company (US) 2013-03-06 EP disclosed
EP-2563508-A2 DELIVERY PARTICLE The Procter & Gamble Company (US) 2013-03-06 EP disclosed
US-20110269657-A1 DELIVERY PARTICLES THE PROCTER & GAMBLE COMPANY 2011-11-03 US disclosed
US-20110268778-A1 DELIVERY PARTICLES THE PROCTER & GAMBLE COMPANY 2011-11-03 US disclosed
US-20110269658-A1 DELIVERY PARTICLES THE PROCTER & GAMBLE COMPANY 2011-11-03 US disclosed
US-20110268802-A1 DELIVERY PARTICLE THE PROCTER & GAMBLE COMPANY 2011-11-03 US disclosed
WO-2010084480-A2 DELIVERY PARTICLES THE PROCTER & GAMBLE COMPANY (US) 2010-07-29 WO disclosed
WO-2010079468-A2 DELIVERY PARTICLE THE PROCTER & GAMBLE COMPANY (US) 2010-07-15 WO disclosed
WO-2010079467-A2 DELIVERY PARTICLES THE PROCTER & GAMBLE COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409497-A1 DELIVERY PARTICLE LIPA, CHMP4B, SLC46A1 ALOX15 1141/4885ALDH1A1 1476/4885NFE2L2 1604/4885
US-20180360706-A1 Delivery Particles LIPA, CHMP4B, ABCB4 ALOX15 909/4885ALDH1A1 1320/4885NFE2L2 1532/4885
US-11628413-B2 Methods of making capsules FUT6, FUT5, LIPA ALOX15 288/4885ALDH1A1 1603/4885NFE2L2 1041/4885
US-20230201786-A1 Methods of Making Capsules FUT6, FUT5, LIPA ALOX15 288/4885ALDH1A1 1603/4885NFE2L2 1041/4885
US-20110268802-A1 DELIVERY PARTICLE LIPA, CHMP4B, SLC46A1 ALOX15 1141/4885ALDH1A1 1476/4885NFE2L2 1604/4885
US-20110268778-A1 DELIVERY PARTICLES LIPA, CHMP4B, ABCB4 ALOX15 909/4885ALDH1A1 1320/4885NFE2L2 1532/4885
US-20110269658-A1 DELIVERY PARTICLES LIPA, CHMP4B, ABCB4 ALOX15 909/4885ALDH1A1 1320/4885NFE2L2 1532/4885
US-20110269657-A1 DELIVERY PARTICLES LIPA, CHMP4B, ABCB4 ALOX15 909/4885ALDH1A1 1320/4885NFE2L2 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.